Fujisawa Pharmaceutical Company, Ltd.

Shigehiro Takase

Masakuni Okuhara

Masanori Okamoto

Masami Ezaki

Hiroshi Hatanaka

Nobuharu Shigematsu

Morita Iwami

Itsuo Uchida

Masanobu Kohsaka

Yasuhisa Tsurumi

Michio Yamashita

Eisaku Tsujii

Hiroshi Imanaka

Seiji Hashimoto

Yasuhiro Hori

Kazuyoshi Umehara

Hiroshi Terano

Masashi Hashimoto

Satoshi Okada

Toshio Goto

Tadaaki Komori

Kazutoshi Sakamoto

Motohiro Hino

Sumio Kiyoto

Motoaki Nishikawa

Hirokazu Tanaka

Kohji Kawabata

Tohru Kino

Hidenori Ohki

Akihiko Fujie

Michizane Hashimoto

Hidenori Nakajima

Tomoko Sato

Keiji Hemmi

Keiji Matsuda

Nobutaka Oohata

Naoki Fukami

Miho Tanaka

Takashi Tojo

Hideo Hirai

Hidetsugu Murai

Nobuyuki Shiraishi

Akira Katayama

Toru Kino

Takanao Otsuka

Keiji Hemmi, Deceased

Kunio Nakahara

Takashi Fujita

Ryuichi Kanasaki

Yoshitada Notsu

Yasuhiko Shinguh

Noriaki Inamura

Koen Verhaeghe

Seiji Yoshimura

Hiroaki Mori

Masanobu Konsaka

The present invention provides a new antimicrobial compound WF14573, and a process for producing WF14573 by (a) culturing a WF14573A and/or B-producing microorganism in a nutrient medium and recovering WF14573A and/or B from the resultant cultured broth or (b) deacylating WF14573A and/or B in the presence of a microbial substance which is capable of deacylating WF14573A and/or B. Also provided are an antimicrobial agent comprising WF14573 and carrier(s), a pharmaceutical composition comprising an effective amount of WF14573 and pharmaceutically acceptable carrier(s), a method for killing microorganisms by applying WF14573 to the microorganisms, and use of WF14573 for the treatment of infectious diseases caused by pathogenic microorganisms.

WF14573 or its salt, production thereof and use thereof

A cyclic tetrapeptide compound and use thereof. Especially, a compound WF27082, a process for production of the compound by culturing, in a nutrient medium, a WF27082-producing strain belonging to Acremonium and recovering the compound from a culture broth, a pharmaceutical composition containing the compound as an active ingredient, in association with a pharmaceutically acceptable, substantially non-toxic carrier or excipient, the compound for use as a medicament, a use of the compound for manufacture of a medicament for inhibiting histone deacetylase, a use of the compound for manufacture of a medicament for treating or preventing inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), protozoal infections, organ transplant rejections, autoimmune diseases, or tumors, a use of histone deacetylase inhibitors as an immunosuppressant or an antitumor agent, and a use of histone deacetylase inhibitors for manufacture of a medicament for treating or preventing organ transplant rejections, autoimmune diseases or tumors are described.

Cyclic tetrapeptide compound and use thereof

The present invention provides a new bioactive compound of formula (I), which has an antimicrobial activity against pathogenic microorganisms, and a process for production thereof. Also provided are a pharmaceutical composition comprising the compound and pharmaceutically acceptable carrier, a use of the WF002 as a medicament and use of the compound for manufacture of the medicament for treatment of infectious disease.

Compound, WF002, production thereof and use thereof

Cyclic hexapeptides having antibiotic activity

The invention relates to new polypeptide compounds represented by the following formula &lsqb;I&rsqb;:

Echinocandine derivatives with antimicrobial activity

Amino acid derivatives and their use as phospholipase A.sub.2 inhibitor

The present invention relates to a novel polypeptide having the following presumed structure: ##STR1## and the compound has both excellent fungicidal and protozoicidal effects.

WF11243 substance

WB2663 substance-producing bacteria belonging to the genus Pseudomonas are cultured to produce a physiologically active substance, from which are isolated neutral substances WB2663A, WB2663B and WB2663C having respective specific rotations

WB2663 substances and method for their production

Production of cyclosporin A and/or C with a strain of NECTRIA

The novel peptides WS-9326A, WS-9326B, their derivatives and pharmaceutically acceptable salts thereof have useful pharmacological activities, particularly in the treatment and/or prevention of asthma and/or pain. A method for the production of the peptides WS-9326A and WS-9326B and derivatives thereof using Streptomyces violaceoniger No. 9326 in a biologically pure form is described herein.

Process for producing WS-9326A and WS-9326B

FR901451 substance, process for preparation thereof and use thereof

A degenerative disease selected from the group consisting of cystic fibrosis, chronic bronchitis and bronchiectasia is treated by administering to a subject a therapeutically effective amount of WS7622A mono-or disulfate or pharmaceutically acceptable salt thereof.

WS7622A mono- or di-sulfate, process for preparation thereof and use

WS7622A mono- or di-sulfate and pharmaceutically acceptable salts thereof. WS7622A exhibits human leukocyte elastase-inhibiting activity.

WS7622A mono- or di- sulfate, process for preparation thereof and use

A method for therapy of disseminated intravascular coagulation, or chronic respiratory tract infectious disease characterized by administering to a patient in need thereof an effective dose suitable for therapeutic treatment of said condition of WS7622A mono- or di-sulfate ester or their pharmaceutically acceptable salt.

Prophylactic/therapeutic composition for disseminated intravascular

Growing community of inventors

Ishioka, Japan

Shigehiro Takase